HPV and Pap test market to grow 7% CAGR, reaching $6.5B by 2034 due to rising cervical cancer awareness.

The global HPV testing and Pap test market is projected to grow at a compound annual growth rate (CAGR) of about 7% from 2026 to 2034, reaching an estimated value of $6.5 billion by 2034. This growth is driven by the increasing prevalence of cervical cancer, enhanced awareness of early screening, government-supported screening programs, and technological advancements such as self-sampling HPV tests and AI-assisted cytology. North America currently leads the market, supported by strong healthcare infrastructure and widespread screening initiatives. The market outlook remains positive as preventive healthcare gains focus and diagnostic companies continue investing in innovative screening solutions.